Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Ultragenyx Pharmaceutical: Q4 Earnings Insights

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM.

Here's what investors need to know about the announcement.

Earnings

Ultragenyx Pharmaceutical missed estimated earnings by 33.58%, reporting an EPS of $-1.79 versus an estimate of $-1.34.

Revenue was up $8.15 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.33, which was followed by a 1.38% increase in the share price the next day.

Here's a look at Ultragenyx Pharmaceutical's past performance:

 

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate -1.41 -1.36 -1.24 -1.16
EPS Actual -1.08 -1.81 -2.03 -0.37
Revenue Estimate 81.55M 85.03M 77.04M 70.54M
Revenue Actual 81.65M 86.97M 99.39M 91.54M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.